company background image
CLBIO logo

Corline Biomedical OM:CLBIO Stock Report

Last Price

SEK 9.26

Market Cap

SEK 203.7m

7D

-11.4%

1Y

-39.5%

Updated

30 Jan, 2025

Data

Company Financials +

CLBIO Stock Overview

Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. More details

CLBIO fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Corline Biomedical AB Competitors

Price History & Performance

Summary of share price highs, lows and changes for Corline Biomedical
Historical stock prices
Current Share PriceSEK 9.26
52 Week HighSEK 15.50
52 Week LowSEK 5.98
Beta0.38
1 Month Change5.47%
3 Month Change15.75%
1 Year Change-39.48%
3 Year Change-26.80%
5 Year Change-38.06%
Change since IPO-9.66%

Recent News & Updates

Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

Aug 24
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

Mar 15
We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

Recent updates

Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

Aug 24
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

Mar 15
We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow

Nov 26
We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow

Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

Jun 22
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth

Feb 16
We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth

Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth

Jun 14
Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth

Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation

Feb 28
Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation

Shareholder Returns

CLBIOSE PharmaceuticalsSE Market
7D-11.4%-0.7%1.1%
1Y-39.5%-1.4%13.3%

Return vs Industry: CLBIO underperformed the Swedish Pharmaceuticals industry which returned -1.4% over the past year.

Return vs Market: CLBIO underperformed the Swedish Market which returned 13.3% over the past year.

Price Volatility

Is CLBIO's price volatile compared to industry and market?
CLBIO volatility
CLBIO Average Weekly Movement9.4%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement5.6%
10% most volatile stocks in SE Market11.7%
10% least volatile stocks in SE Market3.2%

Stable Share Price: CLBIO's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: CLBIO's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
199114Henrik Nittmarwww.corline.se

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company’s products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries.

Corline Biomedical AB Fundamentals Summary

How do Corline Biomedical's earnings and revenue compare to its market cap?
CLBIO fundamental statistics
Market capSEK 203.73m
Earnings (TTM)-SEK 9.63m
Revenue (TTM)SEK 23.56m

8.4x

P/S Ratio

-20.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLBIO income statement (TTM)
RevenueSEK 23.56m
Cost of RevenueSEK 4.35m
Gross ProfitSEK 19.21m
Other ExpensesSEK 28.84m
Earnings-SEK 9.63m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.45
Gross Margin81.53%
Net Profit Margin-40.90%
Debt/Equity Ratio0%

How did CLBIO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 23:19
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Corline Biomedical AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ludvig SvenssonPenser Access